0001101302-25-000103
SEC filingFlat revenue YoY at $807M, margin compression from lower plant performance; net income fell 9% to $70.5M.
For the three months ended September 27, 2025, Entegris reported net sales of $807.1 million, essentially flat compared to $807.7 million in the prior-year period. The slight decline was driven by a $3.3 million volume decrease due to lower semiconductor market demand, partially offset by $2.7 million in favorable foreign currency translation, primarily from the strengthening of the Taiwanese dollar. Gross profit decreased 5.5% to $351.3 million, with gross margin contracting 2.5 percentage points to 43.5%, primarily due to lower plant performance. Selling, general and administrative expenses declined 6.2% to $101.8 million, driven by lower professional fees and employee costs. Engineering, research and development expenses were flat at $80.9 million. Operating income fell 10.0% to $122.6 million, and operating margin declined from 16.9% to 15.2%. Net income decreased 9.0% to $70.5 million, or $0.46 per diluted share, compared to $77.5 million, or $0.51 per diluted share, in the prior year. The effective tax rate dropped to 2.1% from 9.5%, benefiting from the release of unrecognized tax benefits.
On a non-GAAP basis, Adjusted Operating Income declined 8% to $170.3 million, Adjusted EBITDA fell 5% to $220.7 million, and Non-GAAP EPS decreased 6% to $0.72, reflecting lower gross profit partially offset by lower operating expenses.
The Materials Solutions (MS) segment generated net sales of $348.6 million, up 1% year-over-year, driven by increased sales of CMP consumables and cleaning chemistries. However, segment profit decreased 9% to $65.2 million due to lower plant performance, partially offset by lower operating expenses. The Advanced Purity Solutions (APS) segment reported net sales of $460.8 million, down less than 1% year-over-year, mainly due to a decline in facilities-based capital expenditure investments, including fluid handling products and FOUPs. Segment profit decreased 7% to $118.2 million, also impacted by lower plant performance. Unallocated general and administrative expenses decreased 11% to $14.8 million, primarily due to lower non-income tax expense.
Management did not provide explicit forward guidance in the MD&A section, but discussed ongoing impacts from global trade tensions, particularly U.S.-China tariffs, which have increased sourcing and manufacturing costs and may affect demand. The company continues to build a resilient supply chain and global manufacturing footprint to mitigate these risks. Near-term impacts are expected, particularly with high tariffs on products. Additionally, restructuring actions were initiated in the current period, including workforce reductions and asset abandonment, indicating cost optimization efforts. The company remains focused on leveraging its complementary capabilities to deliver integrated solutions for customers in deposition, CMP, and post-CMP modules.
As of September 27, 2025, cash and cash equivalents stood at $399.8M, up from $329.2M at year-end 2024. Total debt, net of unamortized discount and issuance costs, was $3,842.8M, a decrease of $138.3M from $3,981.1M, driven by $150M term loan repayments partially offset by amortization. Shareholders' equity increased to $3,890.8M from $3,691.5M, primarily due to net income of $186.2M and share-based compensation. Inventory was $646.8M, slightly higher than $638.1M at year-end. Contract liabilities (deferred revenue) were $48.8M, up from $41.7M at the beginning of the period.
The notes do not disclose explicit purchase commitments beyond debt maturities. Debt obligations require payments: $400M in 2028, $2,600M in 2029, and $895M thereafter. Operating lease liabilities total $47.9M long-term and $55.5M right-of-use assets. No other material commitments were reported.
For the three months ended September 27, 2025, MS segment revenue was $348.6M (flat YoY), with segment profit of $65.2M (18.7% margin). APS revenue was $460.8M (down 0.5% YoY), with segment profit of $118.2M (25.6% margin). Geographic breakdown shows Taiwan as the largest region ($186.2M), followed by China ($177.9M) and South Korea ($109.8M). North America sales were $135.6M. The segment-level data provides granularity not available in MD&A.
Operating cash flow (CFO) of $503.4M significantly exceeded net income of $186.2M, driven by non-cash charges (depreciation $151.6M, amortization $138.1M, share-based compensation $50.4M) and working capital benefits. The primary working capital sources included a decrease in trade receivables ($7.5M) and an increase in accounts payable and accrued liabilities ($34.5M), partially offset by inventory build ($34.4M) and income tax payments ($41.5M). Capital expenditures of $241.2M represent a 16% increase year-over-year, resulting in a capex-to-CFO ratio of 47.9%. Free cash flow is not explicitly reported, but CFO comfortably covered capex and dividends of $45.7M. Notable anomalies include a $1.7M loss on debt extinguishment and $6.3M impairment of long-lived assets. Financing activities show net debt repayment of $150M and no share repurchases, with dividends being the primary capital return.